“…In turn, agnostic drug scoring approach, including machine learning (ML) methods can offer even a wider spectrum of opportunities by non-hypothesis-driven direct linkage of specific molecular features with clinical outcomes, such as responsiveness on certain types of treatment [7,8]. ML has a variety of methods that could be used for such agnostic approach, e.g., decision trees, DT [9,10], random forests, RF [11], linear [12], logistic [13], lasso [14,15], and ridge [16] regressions, multi-layer perceptron, MLP [10,17,18], support vectors machines, SVM [9,10,19], adaptive boosting [20][21][22].…”